1.55
-0.07(-4.32%)
Currency In USD
| Previous Close | 1.62 |
| Open | 1.69 |
| Day High | 1.69 |
| Day Low | 1.55 |
| 52-Week High | 17.75 |
| 52-Week Low | 1.08 |
| Volume | 169,835 |
| Average Volume | 171,033 |
| Market Cap | 53.72M |
| PE | -2.82 |
| EPS | -0.55 |
| Moving Average 50 Days | 2.13 |
| Moving Average 200 Days | 4.45 |
| Change | -0.07 |
If you invested $1000 in FibroBiologics, Inc. Common Stock (FBLG) since IPO date, it would be worth $88.57 as of February 05, 2025 at a share price of $1.55. Whereas If you bought $1000 worth of FibroBiologics, Inc. Common Stock (FBLG) shares 6 months ago, it would be worth $410.05 as of February 05, 2025 at a share price of $1.55.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing
GlobeNewswire Inc.
Dec 30, 2024 9:30 PM GMT
HOUSTON, Dec. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for c
FibroBiologics Announces $25 Million Financing
GlobeNewswire Inc.
Dec 23, 2024 12:55 PM GMT
HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for c
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
GlobeNewswire Inc.
Nov 19, 2024 2:15 PM GMT
HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases us